Request availability and a quotation for your required quantity and destination.
| Product | Semaglutide 1 mg - Ozempic Pen |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Active ingredient: Semaglutide
Listed strength: 1 mg
Form: Subcutaneous injection pen
Class: GLP-1 receptor agonist
Supply: Prescription and destination-country regulations apply
Ozempic 1 mg is a once-weekly semaglutide injectable used for type 2 diabetes. The 1 mg strength is not the typical initial dose; dose escalation is clinician-directed. Product-specific indications and age limits differ internationally; verify the leaflet and the exact pen presentation before use.
Ozempic is prescribed to improve glycaemic management in eligible patients with type 2 diabetes. Depending on the current regional label, additional risk-reduction indications may apply. It should not be marketed as an interchangeable substitute for a separately approved weight-loss treatment.
Semaglutide activates GLP-1 receptors, influencing glucose-dependent insulin secretion, glucagon release and gastric emptying. Appetite effects can occur. This does not mean every person will experience the same glycaemic or weight response.
Ozempic is generally injected once a week. Only follow the dose schedule and injection instructions provided by the prescriber and manufacturer. Subcutaneous sites include abdomen, thigh or upper arm depending on the product leaflet. Do not share pens, even if needles are changed. Do not alter the strength, reuse needles or combine GLP-1 medicines without professional guidance. Discuss storage and temperature-control requirements before international supply.
GLP-1 treatments carry clinically significant warnings. U.S. labeling includes a boxed thyroid C-cell tumor warning and contraindicates use with personal or family history of medullary thyroid carcinoma or MEN2. A previous serious allergic reaction to the active ingredient is also a contraindication. Discuss pregnancy, planned surgery requiring anaesthesia or deep sedation, pancreas or gallbladder disease, kidney problems, severe gastrointestinal effects and all concurrent medicines with the clinician.
Potential adverse effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. Dehydration can contribute to kidney injury; hypoglycaemia may be more likely with insulin or sulfonylureas. Seek prompt medical care for persistent severe abdominal pain or allergic symptoms. Diabetic retinopathy and product-specific label precautions warrant review.
Explore Ozempic 0.5 mg, Ozempic 1 mg and oral semaglutide – Rybelsus 3 mg. Read the existing Cureiva Related Cureiva readingsemaglutide product comparison for context. Links are educational, not substitution advice.
Review the Ozempic official prescribing information and the leaflet supplied with the actual product. Local indications may differ.
Yes. Appropriate medical assessment, documentation and local prescribing regulations apply.
Not necessarily. The listed strength identifies a particular pen presentation; the prescriber must determine the injection regimen.
Do not switch or combine products without clinical guidance because dosing, indications and risk profiles differ.
Manufacturer storage instructions may require refrigeration before first use and specific temperature limits afterward. Check the exact pack and shipping feasibility.
No. Availability depends on prescribing requirements, product authenticity checks, transport suitability and destination-country rules.
No. Ozempic treatment typically begins with a lower dose and is escalated according to the specific product label and clinician’s plan.
Ozempic is generally injected once weekly as prescribed.
Do not switch formulations without clinician guidance; dosing and conversion considerations differ.
Follow the exact pen’s leaflet. For U.S. Ozempic labeling, a missed dose may be taken within five days; otherwise skip and resume the scheduled day.
Severe persistent abdominal pain, serious allergic symptoms and significant dehydration require prompt medical assessment.
Cureiva Healthcare handles business and individual-patient product enquiries where permitted. This information is educational, is not a personal medical recommendation and does not claim individual physician review.
Reference check: October 2026.